Natco Pharma Limited (NSE: NATCOPHARM) announced the completion of acquiring an additional 13.25% stake in Adcock Ingram, boosting its ownership to 49%.
Natco Pharma Limited (NSE: NATCOPHARM) stock rises 5% intraday to ₹983.6, showing a fresh upward trend despite a breakdown status. Follow the latest updates.
Natco Pharma Limited (NSE: NATCO PHARM) announces FDA approval for Eribulin Mesylate Injection, a bioequivalent to Halaven®.
